Abstract 61P
Background
Total neoadjuvant therapy is a combination of radiotherapy and chemotherapy for treatment of locally advanced rectal cancer, in any sequence, though RAPIDO and PRODIGE -23 have focused on this treatment protocol, in India there is no such trial done now.
Methods
Study design: Prospective interventional single-arm feasibility study. Study duration: August 2020 to May 2021. Study setting: Department of Radiotherapy in collaboration with Department of Surgical Oncology, Department of General Surgery of King George’s Medical University in Lucknow, India. Sample size 30. Sampling technique: All patients who attended radiotherapy opd during this study duration. Selection criteria: ECOG 0-1 patients with locally advanced stage I-III adenocarcinoma of middle or lower rectum. Study course: Patients received short course radiotherapy (SCRT) (25 Gray in 5 fractions over one week ) followed by six cycles of chemotherapy (Inj. oxaliplatin 130 mg / m2 on day one and Tab. capecitabine 1000 mg/m2 bid for 14 days- q3weekly). After completion of chemotherapy, all patients were sent for surgical evaluation. Objectives were to study immediate surgical outcomes in terms of pathological complete response (pCR), R0 resection rate, circumferential resection positive rate.
Results
Among the 30 recruited subjects, 6 (20%) were male and 24 (80%) were female, presentation is bleeding per rectum followed by pain and altered bowel habits. 60% were vegetarian in diet. All patients were histo-pathologically proven adenocarcinoma among 20% were signet ring types. 40% of the patients were well differentiated adenocarcinoma. 70% were T3 stage, and node positive disease. 63% of the patients had lower rectal disease. 83% had mesorectal fascia involvement. 50% had raised CEA (>5ng/ml ). 75% completed 6 cycles of chemotherapy along with 70% grade I neuropathy. 20% had grade 3 diarrhoea. 25 patients got operated. The surgical outcomes are described in the table. Table: 61P
No. of patients (n=25) | % | |
Sphincter preservation | 4 | 16.0 |
Pathological complete response | 5 | 20.0 |
Total mesorectal excision | 25 | 100.0 |
Circumferential resection margin positive | 2 | 8.0 |
R0 rate | 23 | 92.0 |
Conclusions
Intensification of this therapy has potential to increase proportion of patients who achieve complete clinical response (cCR) and could be a candidate for wait and watch.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
119P - Clinicopathological features and roles of lymph node metastases in gastric cancer: A single-center retrospective study in China
Presenter: yuming zhang
Session: Poster viewing 02
120P - Clinical implication of DNA damage response gene in advanced gastric cancer stage IV and recurrent gastric cancer patients after gastrectomy treated palliative chemotherapy
Presenter: In Gyu Hwang
Session: Poster viewing 02
121P - Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
Presenter: Amrith B P
Session: Poster viewing 02
122P - Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Presenter: Amrith B P
Session: Poster viewing 02
123P - Sarcomatoid carcinoma of gall bladder: A series of 14 cases from a single tertiary-care oncology centre
Presenter: Subhash Yadav
Session: Poster viewing 02
124P - Clinical profile and treatment outcomes of hepatocellular carcinoma from a tertiary care hospital in South India: A retrospective study
Presenter: Gayathri Nair
Session: Poster viewing 02
125P - A parametric network meta-analysis of PD-1 inhibitors in second-line treatment for advanced esophageal squamous cell carcinoma
Presenter: Shubhram Pandey
Session: Poster viewing 02
126P - Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Presenter: Keitaro Shimozaki
Session: Poster viewing 02
127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Presenter: Jirapat Wonglhow
Session: Poster viewing 02
128P - Survival outcome of gastric cancer patients in a tertiary care center: A 10-year single center retrospective study
Presenter: Dawn Lynn Guardiario
Session: Poster viewing 02